 Sign in or create an account

About Tools Developers Help Europe PMC plus

About Europe
Search worldwide, life-sciences literature Tools
PMCoverview
Developer resources
Help using Europe PMC

Funders ORCID article

Articles RESTful
claiming Search
Contact
API us Advanced Search

E.g. "breast cancer" HER2 Smith J

Joining Europe
Journal
PMC listGrants RESTful API

Governance
Grant finder
SOAP web service
 Recent Activity  Export Tweet

Roadmap External links

Annotations
service API

Outreach RSS feeds OAI service

SciLite annotations
Bulk downloads

 Feedback
 Pharmacological effects and potential therapeutic targets of DT-13.
(PMID:29107216)

1 2 3 4 5 6 7 8 9
Khan GJ  , Rizwan M  , Abbas M  , Naveed M  , Boyang Y  , Naeem MA  , Khan S  , Yuan S  , Baig MMFA  , 
10
Sun L   

Affiliations 

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie [28 Oct 2017, 97:255-263]

Type: Review, Journal Article

DOI: 10.1016/j.biopha.2017.10.101

Abstract

DT-13 is an isolated compound from Dwarf lillytruf tuber and currently among active research drugs by National
Natural Science foundation of China for its several potential effects. The drug has been reported for its multiple
pharmacological actions however no thorough review studies are available on it. Our present study is
highlighting the pros and cons of DT-13 focusing on its potential pharmacological actions, therapeutic utilization
and further exploration for novel targets. The drug possesses very low toxicity profile, quick onset and long
duration of action with slow elimination that combinely makes it favorable for the clinical studies. In vivo and in
vitro studies show that the drug regulates multiple cellular functions for its several pharmacological effects
including, anti-adhesive effects via regulation of tissue factor and transforming growth factor; anti-migratory
effects through indirect regulation of NM-IIA in the tumor microenvironment, Tissue factor, down-regulation of
CCR5-CCL5 axis and MMP-2/9 inhibition; anti-metastatic effects via regulation of MMPs and tissue factor; pro-
apoptotic effects by modulation of endocytosis of EGF receptor; anti-angiogenic effects via regulation of HIF-
1α,ERK, Akt signalling and autophagy inducing characteristics by regulating PI3K/Akt/mTOR signalling pathway.
In addition to anti-tumor activities, DT-13 has significant anti-inflammatory, cardioprotective, hepatoprotective
and immunomodulating effects. Pharmaceutical dosage form and targeted drug delivery system for DT-13 has
not been established yet. Moreover, DT-13, has not been studied for its action on brain, colorectal, hepatic,
pancreatic, prostate and blood cancers. Similarly the effects of drug on carbohydrate and glucose metabolism is
another niche yet to be explored. In some traditional therapies, crude drug from the plant is used against
diabetic and neurological disorders that are not reported in scientific literature, however due to profound
effects of DT-13 on blood and cerebral ischemic disorders, it is reasonable to hypothesize that there could be an
association of DT-13 that require further exploration.

Read Article at publisher's site 

Formats

Abstract Full Text 

Show annotations in this abstract

Chemicals
Diseases  Feedback
 Gene Ontology
Genes/Proteins

About Tools Developers Help Contact us

About Europe PMC Tools overview Developer resources Help using Europe PMC Helpdesk
Funders ORCID article claiming Articles RESTful API Contact us Feedback
Joining Europe PMC Journal list Grants RESTful API Twitter
Governance Grant finder SOAP web service Blog
Roadmap External links service Annotations API
Outreach RSS feeds OAI service
SciLite annotations Bulk downloads

Europe PMC is part of the ELIXIR infrastructure

Europe PMC is an Elixir Core Data Resource Learn more ›

Europe PMC is a service of the Europe PMC Funders' Group, in partnership with the European Bioinformatics Institute; and in
cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine (NCBI/NLM). It includes
content provided to the PMC International archive by participating publishers.

   
Contact Us | Terms of Use | Copyright | Accessibility | Cookies

 Feedback